34
nanotimes
Companies Facts
collect samples (like rodent serum, spinal fluid, tissue extracts, tears and dried blood spots) are possible. And with femtofluidic liquid handling, the NanoArray Assay System™ delivers rapid reaction kinetics and lowers reagent volumes, reducing assay costs.”
http://www.nanoink.net/nanobio
N
anometrics Incorporated (NASDAQ: NANO), announced the opening of its Singapore Advan-
ced Metrology Center, an applications development center for customers using Nanometrics metrology systems. The center provides dedicated support throughout Asia for customers requiring advanced modeling of complex structures and recipe develop- ment. Nanometrics investment and commitment to additional applications resources reflects the rapid growth and adoption of optical critical dimension (OCD) technology in semiconductor manufacturing due to smaller, more complex structures and new materials.
Furthermore, Nanometrics announced a new release of NanoCD™ Suite, a turnkey optical critical dimen- sion (OCD) analysis solution with advanced modeling and recipe building capabilities. The suite, which is composed of high-performance software and hard- ware components, addresses process control requi- rements for semiconductor devices in production at 2x nm nodes and development at 1x nm nodes. The new product incorporates NanoDiffract™ 3.0, a pro- prietary OCD software engine broadly adopted by the world’s leading memory and logic customers and production proven at 2x nm technology nodes.
http://www.nanometrics.com
N
anosphere, Inc. (NASDAQ: NSPH) released early stage research data on potential cancer
biomarkers requiring high sensitivity in an abstract for the annual meeting of the American Society of Clinical Oncology (ASCO, Chicago, USA, June 3 to 7, 2011). The early data suggests that three of Nanosphere‘s ultra-sensitive protein assays demons- trate potential clinical relevance in bladder, kidney and prostate cancers. The assays were developed and run using the Verisens™ high-throughput re- search platform.
http://abstract.asco.org/AbstView_102_84952.html
F
or the 2010 fiscal year, Frankfurt-based nano- technology investment company Nanostart AG
(OTCQX: NASRY) reports the biggest profit in its company history. Net income under German GAAP totaled EUR2.48 million, up 106% on the previous year (2009: EUR1.2 million). This means another successful year for Nanostart, which has been profita- ble from the beginning of operations.
Net income stemmed chiefly from the successful sale of shares in holdings, which raised around EUR4.4 million. In contrast to the previous year, costs were reduced, particularly for wages and salaries (2010: EUR-0.5 million, 2009: EUR-1 million). As a result of sound performance levels in the portfolio, the “write- downs on financial investments” item was halved from EUR-1.4 million in 2009 to EUR-0.7 million in 2010.
The shares of Nanostart Singapore Early Stage Ven- ture Fund I in the Curiox Biosystems holding were sold in 2010. The transaction proceeds were plowed back into the fund and will be invested in new nano-
11-05 :: May/June 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95